Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin-17A^[2].
Secukinumab (1 nM, 10 nM, and 100 nM) inhibits IL17A and IL17A/TNF a-induced increase in protein levels of IL6 in human astrocytes^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

• 
  Human IgG1 kappa

• 
  Immobilized IL-17A Protein, Human (HEK293, His, HY-P70527) can bind Secukinumab. The EC₅₀ for this effect is 16.2 ng/mL.

• [1]. Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76(11):1135-1145.  [Content Brief]

  [2]. Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304-315.  [Content Brief]

  [3]. Elain G, et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62(5):725-735.  [Content Brief]